Articles tagged "B cells"

2018 American Transplant Congress
CD19+ Cell Ratio as a Predictive Marker of Antibody Mediated Rejection in ABO Incompatible Kidney Transplantation
K. Unagami,¹ R. Maenosono,² M. Furusawa,² Y. Kakuta,² M. Okumi,² H. Ishida,² K. Tanabe,² K. Nitta.¹
¹Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan.
Background: Rituximab has been suggested to deplete B cells and decrease the possibility of antibody mediated rejection (AMR) in ABO-incompatible living kidney transplantation (ABO-ILKT). We…
2018 American Transplant Congress
Targeting Plasma Cells with Anti-CD38mAb (Daratumumab) and CXCR4 Antagonist (Plerixafor) for Desensitization
J. Kwun,¹ E. Brian,¹ M. Manook,¹ J. Park,¹ K. Freischlag,¹ J. Yoon,¹ J. Yi,¹ M. Stegall,² S. Knechtle.¹
¹Surgery, Duke University, Durham, NC; ²Surgery, Mayo Clinic, Rochester, MN.
[Introduction] Sensitized patients comprise a significant portion (30%) of candidates on the transplant waiting list. Unfortunately for sensitized patients, the presence of donor-specific antibodies (DSA)…
2018 American Transplant Congress
The Incidence of Polyomavirus-BK and Cytomegalovirus Infections in Renal Transplant Recipients Following Rituximab Administration
A. Kraljevic, C. D'Agostino, C. Kane, K. Cunningham, A. Shetty, C. Richardson.
Northwestern Memorial Hospital, Chicago, IL.
Rituximab is an antibody that binds to the CD20 antigen on B cells resulting in rapid and prolonged depletion. At Northwestern Memorial Hospital, a single…
2018 American Transplant Congress
Impact of De Novo DSA (DnDSA) on Outcomes in HLA-Sensitized (HS) Patients Transplanted after IVIG + Rituximab Desensitization (DES)
A. Vo,¹ O. Aubert,² H. Edmund,¹ A. Peng,¹ R. Najjar,¹ S. Supreet,¹ J. Choi,¹ K. Lim,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Paris Translational Research Center for Organ Transplantation, Necker Hospital, Paris, France.
Introduction: Highly-HLA sensitized patients (HS) with donor specific antibodies (DSA) at transplant are at risk for Type 1 ABMR. However, the incidence of Type 2…
2018 American Transplant Congress
TACI Polymorphisms Associated with Allograft Rejection in Mice and in Man
M. Barbosa,¹ E. Farkash,² J. Platt,³ M. Cascalho.³
¹Surgery, University of Michigan, Ann Arbor, MI; ²Pathology, University of Michigan, Ann Arbor, MI; ³Surgery/Microbiology and Immunology, University of Michigan, Ann Arbor, MI.
Trans-membrane Activator and CAML Interactor (TACI) controls B cell differentiation and memory and exists as numerous allelic variants in healthy individuals. In fact, TACI is…
2018 American Transplant Congress
Prolonged Cold Ischemia Storage of Renal Allografts Shifts DSA Specificity and Enchances Glomerular Injury
V. Gorbacheva, R. Fan, W. Baldwin, A. Valujskikh.
Immunology, Cleveland Clinic, Cleveland, OH.
Prolonged cold ischemia storage (CIS) of donor organs is a major risk factor for acute and chronic graft injury. The goal of this study was…
2018 American Transplant Congress
Elevated Levels of CD19⁺ B Cells before or after Rituximab Administration is a Risk Factor for the Early Rejection of a Living Kidney Transplant
M. Kono,¹ H. Shirakawa,² S. Wakai.¹
¹Nephrology, Ohkubo Hospital, Tokyo, Japan; ²Urology, Ohkubo Hospital, Tokyo, Japan.
[Introduction]Rituximab (RTX) is used for desensitization in highly sensitized patients, such as those undergoing ABO-incompatible (ABOi) kidney transplantation. Although RTX is generally effective, some patients…
2018 American Transplant Congress
In Vivo Administration of Plerixafor and Bortezomib Results in Bone Marrow Plasma Cell Mobilization and Death While Inducing Biphasic Plasma Cell Apoptosis in Peripheral Blood
E. Woodle,¹ S. Tremblay,¹ C. Castro-Rojas,² S. Knechtle,³ A. Shields,¹ R. Alloway,¹ H. Singh,² J. Driscoll,¹ D. Hildeman.²
¹U Cincinnati, Cincinnati; ²Cincinnati Children's, Cincinnati; ³Duke, Durham.
Bone marrow (BM) plasma cells (PC) secreting HLA antibody (Ab) remain a persistent reservoir of donor specific Ab and present a significant hurdle to allograft…
2018 American Transplant Congress
Genomic Modifications Associated with Epstein Barr Virus+ Post-Transplant Lymphoproliferative Disorder
M. McPherson,¹ Y. Balachandran,¹ S. Boyd,² H. Zimmermann,³ R. Trappe,³ C. Esquivel,¹ S. Krams,¹ O. Martinez.¹
¹Department of Surgery, Stanford University School of Medicine, Stanford, CA; ²Department of Pathology, Stanford University School of Medicine, Stanford, CA; ³Department of Haematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Bremen, Germany.
Epstein Barr Virus (EBV) is nearly ubiquitous in the human population, yet EBV infection is typically asymptomatic. Nevertheless, immunosuppressed transplant recipients are susceptible to EBV+…
2018 American Transplant Congress
Pancreas Transplant for Type 2 Diabetes is Associated with Preserved Function, but Impaired Glucose Tolerance: A Comparative Analysis
S. Doshi, C. Pulitano, D. Al-Adra, A. Norgate, G. Sapisochin, M. Selzner, I. McGilvray, J. Schiff, M. Cattral.
Multi-Organ Transplant Program, Toronto General Hospital, Toronto, ON, Canada.
Background: The indications and outcomes of pancreas transplantation for type 2 diabetes mellitus (T2DM) remains controversial. The aim of this study was to compare the…